2025 AMA Research Challenge – Member Premier Access

October 22, 2025

Virtual only, United States

Would you like to see your presentation here, made available to a global audience of researchers?
Add your own presentation or have us affordably record your next conference.

Abstract Title Ovarian Cancer with Gastric Metastasis: A Rare Presentation

Background Metastatic gastric malignancy is rare, representing 0.7-5.4% of all gastric cancers. The most common tumors metastatic to the stomach are the breast and lung cancer, and melanoma. Gastric metastasis from ovarian serous cancer is extremely rare, accounting for only 0.013% to 1.600% of all gastric metastatic tumors. We present a case of ovarian cancer metastasizing to the stomach presenting with symptomatic anemia.

Case Presentation A 64-year-old female patient with past medical history of low grade serous ovarian cancer S/P simple hysterectomy and oophorectomy five years ago with metastatic disease to the liver, lung, and peritoneum, S/P Carboplatin and Taxol three months ago and currently receiving BRAF directed therapy (Dabrafenib/Trametinib), presented from medical oncology office after being found with a low hemoglobin of 6.4. Patient also reported symptoms of fatigue, nausea, lightheadedness and shortness of breath. Patient denied any melena or hematochezia. On examination, vital signs were stable and physical examination was unremarkable. CT abdomen showed intraabdominal mass with progression and likely infiltration into stomach within the lumen. A prior esophagogstroduodenoscopy (EGD) six months ago was normal. Patient received blood transfusion and underwent an EGD which showed a large, fungating, infiltrative, polypoid and ulcerated, partially circumferential (involving one-third of the lumen circumference) mass with no bleeding and no stigmata of recent bleeding in the gastric fundus. Surgical pathology was consistent with serous carcinoma with psammomatous calcification with immunostains positive for PAX8, p16, p53, estrogen receptor and CK7. Patient was treated with Ribociclib and Fulvestrant and received palliative radiation to the abdomen to control gastrointestinal bleeding and abdominal pain. Therapy was changed from Ribociclib to Trastuzumab deruxtecan as the patient was intolerant to Ribociclib and due to the IHC from the gastric mass being HER2 1+ positive. Subsequent PET CT showed shrinkage of intraabdominal mass and liver lesions.

Discussion The most common symptoms of ovarian cancer with gastric metastasis are abdominal pain, anemia, vomiting, and melena. It is important to distinguish a primary gastric malignancy from metastatic disease with ovarian origin in a patient with history of ovarian cancer presenting with anemia.

Next from 2025 AMA Research Challenge – Member Premier Access

Hypertensive Crisis Unresponsive to Standard Therapy: The Interplay of Pulmonary Hypertension and Scleroderma Renal Crisis in Systemic Sclerosis

Hypertensive Crisis Unresponsive to Standard Therapy: The Interplay of Pulmonary Hypertension and Scleroderma Renal Crisis in Systemic Sclerosis

2025 AMA Research Challenge – Member Premier Access

Gurpreet Kaur

22 October 2025

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Presentations
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2025 Underline - All rights reserved